Report warns Turkey's pharma boom is restricted by government reimbursement

Turkey is a key destination for foreign investment, with big pharma increasingly looking at facilities within the country, according to a Pharma Insights report on the country from CPhI Worldwide.

The report, to be presented at CPhI Istanbul next week, includes analysis of the Turkish pharma market conducted amongst all major Turkish manufacturers, evaluating conditions for both foreign and domestic companies.

Chris Kilbee, group director pharma, said the report points towards an increasingly prosperous and innovative marketplace. He said: “Growth domestically and as key regional hub for pharma products supply has firmly put Turkey on the global pharma map. What we are now seeing is an evolution of the industry internally with bold investments being made in biologics and even R&D programs.